Introduction
Inflammation plays a key role in cancer physiology, as it could promote carcinogenesis, dedifferentiation, and primary tumour growth [1] ; furthermore, it promotes tumour cells proliferation by inhibiting apoptosis and increasing mitosis rate [1] .
Inflammation has also some protective effects, participating in the initial anticancer response, mainly by cell-mediated immunity; immune cells can recognize factors produced by the inflammatory response in tumour to detect lymphocytes, macrophages, and dendritic cells (the so-called paradox of inflammation) [2] ; inflammation has a causative role in many tumours and is a concomitant event in malignant recurrence [1] .
As the role of inflammatory response is strictly connected with cancer physiology, many studies have investigated its role in cancer outcome. Regarding cancer surgery, systemic inflammatory response (SIR) has actually been shown as an important prognostic factor associated with lower postoperative survival in several types of cancer.
Considering this prognostic value, the new challenges for physicians are represented by detecting degree of inflammation in each patient through specific inflammatory markers, clearly correlated with prognosis and able to preoperatively recognize immune changes for a better stratification of 2 BioMed Research International patient's risk. As inflammation is a complex phenomenon involving many cells and cytokines both systemically and locally (within the tumour), finding a low-cost, highly reliable, and easy to detect marker is often difficult. So far, a number of different prognostic scores based on inflammation have been proposed, with an increasing evidence of their value but with limits in their sensitivity and specificity. The role of this review is to focus on the currently studied and validated scores, in order to clarify their rationale and to analyze the actual evidence and limits, providing physicians with an updated overview of the possible inflammation-based prognostic scores for cancer patients undergoing surgery.
Methods
We systematically identified reports of studies assessing the use of inflammation-based scores. PubMed and MEDLINE databases were searched until November 2013 using the terms: "platelet to lymphocyte ratio" or "neutrophil to lymphocyte ratio" or "Glasgow prognostic score" and "cancer outcome. " Only papers in English were considered. Additional reports were identified from reference lists of retrieved papers. Only full papers were considered.
Included studies were both prospective and retrospective; retrospective analyses of prospective data were included and listed as retrospective (Tables 2 and 3) .
Principal outcome measures were overall survival, disease-free survival, time to recurrence, pathology-free survival, relapse-free survival, mortality, and tumor resectability.
We included studies in which a selected marker was demonstrated to have a prognostic value alone or in combination with other markers (not strictly connected with inflammation).
We included studies involving only human subjects, both surgical and nonsurgical patients.
Results
The initial electronic literature searches revealed 136 studies, and, after evaluation of the abstracts, 78 were identified as potentially meeting the inclusion criteria. Evaluated inflammatory markers were NLR (neutrophil to lymphocyte ratio), PLR (platelet to lymphocyte ratio), GPS (Glasgow prognostic scale), and mGPS (modified GPS). 58 studies were excluded because they were about (1) inflammation markers other than NLR, PLR, and (m) GPS, (2) cancer noninflammation markers, (3) prognostic but not inflammation-based scores specifically relating to a single type of tumor, (4) cancer survival associated with different chemotherapies, and (5) effect of "other" variables on patient's outcome (infections, BMI, cigarette smoke, nutritional status, depression, psychological interventions, different surgical approaches, hemodynamic instability, reoperations, and graft histologic patterns). One study was excluded because it was not in English, while one study was excluded because it was a poster abstract of a scientific meeting. 36 additional studies were identified from reference lists of retrieved papers; additional evaluated 
Glasgow Prognostic Score.
Glasgow prognostic score (GPS) measures acute-phase protein markers of the SIR, namely, C-reactive protein and albumin using standard thresholds (>10 mg/L for C-reactive protein and <35 g/L for albumin), which were combined to form a cumulative inflammation-based prognostic score [58] . This was subsequently refined to form the modified Glasgow prognostic score (mGPS) [59] when, in patients with primary operable colorectal cancer, hypoalbuminemia alone was found to have the same prognostic value as a GPS of 0 ( Table 1) . The higher the score is, the higher the risk is; an increased mGPS was predictive of a reduced cancer-specific survival in all cancers [56] . GPS is considered as a measure for systemic inflammation and reflects some of the biological changes, in both immune response and nutritional status, associated with cancer patients. The connection between systemic inflammation and mGPS is mainly acted through interleukin 6 (IL-6) role, as it is a pleiotropic cytokine with many physiological actions. In fact, IL-6 promotes not only CRP upregulation, but also albumin downregulation in the liver, as well as protein synthesis [60] and thrombocytosis [61] ; it is also important to underline that some of these characteristics are related to nutritional status, because an elevated CRP level, hypoalbuminemia, and low BMI reflect cachexia due to hypercytokinemia resulting from tumour progression.
The evidence that the inclusion of a leukocyte count may add prognostic value to the validated mGPS and the recent introduction of high-sensitivity C-reactive protein measurements in routine clinical laboratory analysis (with threshold sensitivity lowered to 0.05 mg/L) has further modified the C-reactive protein/albumin combination improving the prognostic value derived from the components of a differential leukocyte count (neutrophil, lymphocyte, and platelet counts), as demonstrated in a recent paper in which the addition of neutrophil and platelet counts, as well as a high-sensitivity C-reactive protein, enhanced the prognostic value of the mGPS [57] . GPS has been reported, in more than 60 studies (>30,000 patients), with independent prognostic value in patients with cancer in a heterogeneous variety of clinical scenarios and tumour types [62] .
Currently, the GPS/mGPS is the most extensively validated one of the systemic inflammation-based prognostic scores and therefore may be used in the routine clinical assessment of patients with cancer, in addition or in preference to the current definitions of cachexia, together with tumour staging [62] .
This biomarker not only identifies patients at risk for poorer prognosis but also provides a well-defined therapeutic target for treatment and future clinical trials. For example, patients with elevated mGPS scores should be considered in a precachexia status and offered with multimodal therapy (surgical tumour excision, anti-inflammation strategies, and metabolic and nutritional surveillance), which may delay the onset of cachexia and/or death [63] ; anesthetic and surgical techniques able to reduce the enhanced inflammatory reaction after surgery could be planned in patients with higher basal inflammation. As a consequence, this will highlight the need to treat not only the tumour itself but also the SIR, a potentially more tractable target compared with well-established weight loss and/or poor performance status. Further studies are required to define the value of GPS/mGPS as a stratification factor, as selection criteria in randomized clinical trials, and as a therapeutic target in patients with cancer [62] .
Neutrophil to Lymphocytes
Ratio. Neutrophil to lymphocytes ratio (NLR) is one of the most studied inflammation prognostic markers for postoperative outcome. In fact, as it is well related to inflammation response, its role in identifying high-risk patients has been proposed in cancer and noncancer patients (see Table 2 ).
Different studies have highlighted the role of a high NLR as a preoperative tool to detect cancer patients with poorer prognosis, in terms of both general comorbidities and cancer disease-free and overall survival [64] . Furthermore, some studies have identified NLR as a valid tool to identify patients who are more sensitive to specific chemotherapy regimen both in the surgical and nonsurgical setting [5, 16, 28, 33, 35, 45, 55] .
NLR is simple and reliable, being part of the standard exams for clinical evaluation, and can be assessed both preoperatively and postoperatively. Even if the majority of studies evaluate this marker in the preoperative setting, its prognostic value has been associated also with postoperative value, in terms of short-term morbidity and long-term mortality [20, 23, 28, 39, 43, 46, 49] .
The relation between NLR and cancer outcome is probably to be found in tumour-associated immune changes; an elevated NLR reflects a decreased lymphocyte-mediated immunity (with an alteration in CD4+ helper/CD8+ suppressors ratio) and an increased production of inflammatory agents such as vascular endothelial growth factor (VEGF) that promotes tumour growth [65] ; some studies evidence that the highest values of NLR are associated with aggressive tumour profiles [52] . Other studies focus on the NLR trend during tumour history, showing that a persistently high value is associated with poorer outcome (Table 2) ; all these findings suggest a probable direct connection between cancer biology and systemic inflammation expressed by NLR.
Even though most of the studies are retrospective, they reach the same conclusions. There are currently few prospective studies assessing the prognostic value of NLR, and a lack of homogeneity still exists in the definition of a standard NLR cutoff associated with different prognoses (Table 2) ; maybe different cutoffs have to be established for different types of cancer, as each type of cancer is associated with different changes in immune response.
The Role of Reactive Thrombocytosis: Platelet Count, COP-NLR, and Platelet to Lymphocyte Ratio.
Recent studies have demonstrated that reactive thrombocytosis is associated with lower survival after surgery for several types of cancer [66] [67] [68] [69] , and platelet count could be related to the SIR, even if it is not still known which is the exact link between platelet, inflammation, and cancer outcomes. Reactive thrombocytosis is induced in a background of hypercytokinemia related to tumour progression. Among several inflammatory cytokines, IL-6 plays an important role in reactive thrombocytosis [61] . IL-6 has a cell-proliferative effect, triggering the differentiation of megakaryocytes to platelets in the bone marrow [70, 71] .
Although the normal platelet count is 15-30 × 10 4 mm 3 , the cutoff value for reactive thrombocytosis is not clearly defined. However, most previous studies have used a cutoff value of 30-40 × 10 4 mm 3 [72, 73] . More studies are needed also to confirm the validity of this cutoff value.
Thrombocytosis is also induced from the tumour itself [74] . Generally, thrombocytosis is a laboratory finding in 10-57% of patients with malignancy, as a variety of neoplastic cells can stimulate platelet activation [75, 76] ; some studies have revealed that cancer cells secrete vascular endothelial growth factor (VEGF), which also stimulates megakaryocyte differentiation [77] . Because VEGF induction promotes tumour growth [74, 78] , thrombocytosis indirectly reflects tumour progression; a high level of VEGF is found in serum, platelets, and leukocytes of patients with malignant disease [79] , and platelet interactions with malignant cells promote metastasis [80] .
Shimada et al. [69] have reported an association between high NLR and high platelet count in gastric cancer prognosis and also found that reactive thrombocytosis [81] was associated with lower postoperative survival in patients with esophageal cancer. Other studies confirmed a high platelet count as a negative prognostic factor for renal cell, pancreatic, and colorectal cancers [72, 73, [82] [83] [84] .
These results gave strong support to the use of a combination of reactive thrombocytosis and the NLR for prediction of postoperative survival; in a recent work by Ishizuka et al. [85] presented the COP-NLR (combination of olatelet count and neutrophil to lymphocyte ratio), for predicting the postoperative survival of patients with colorectal cancer. In their study patients were divided in 3 groups based on presence or absence of platelet count >300.000/mm 3 and NLR > 3 and a statistically significant difference in cancer specific survival were retrieved, with COP-NLR being able to classify patient's outcome into three independent groups. Moreover, COP-NLR resulted associated with tumour-related characteristics (type and dimension, invasivity and metastasis, operative curability, CEA) and SIR-related characteristics (high CRP, hypoalbuminemia, low BMI, and high NLR). These findings suggest the new COP-NLR as a new inflammation-based prognostic marker to complement classical tumour staging, reflecting biological changes related to high levels of IL-6 (the theoretically ideal marker of tumour-related SIR, whose serum levels are often difficult to be measured in the clinical practice). As there is only this retrospective study, more data are needed to confirm its predictive value demonstrating its specificity in other types of cancer. Nevertheless COP-NLR seems a valuable and promising tool for patient stratification in colorectal cancer.
Another prognostic marker related to platelet proliferation is the platelet to lymphocyte ratio (PLR).
PLR has been identified as a prognostic marker in patients with advanced gastric cancer [55] treated with chemotherapy (identifying more sensitive patients to specific type of chemotherapy), and its preoperative value correlated with prognosis (Table 3) . Like NLR, studies are mainly retrospective and about only a few types of cancer; moreover, a lack of homogeneity still exists in the definition of a standard PLR cutoff associated with different prognoses. Further studies are needed to understand the real role of this marker and if it has a higher or lower prognostic value relating to NLR [6, 7] .
Discussion
As inflammation is strictly related to cancer, SIR is demonstrated to influence cancer patients' outcome.
In the last decade research focused its attention on finding specific biomarkers able to quantify systemic inflammation, in order to stratify patients' risk and detect patients more prone to be treated with different therapies, especially in cancer patients undergoing surgery.
These markers are not always simple or cheap to measure, so efforts have been done to find a low-cost, highly reliable, and easy to detect biomarker, clearly associated with prognosis and easily evaluated with routine laboratory analysis. Existing evidence suggests that a higher prognostic value is associated not with a single marker but with a combination of them; inflammation-based scores reflect many biological changes connected with cancer, and the impact of systemic inflammation on various aspects of patient's physiology [86, 87] .
Among these inflammation-based scores, GPS is the most extensively validated one. It may be used in the routine clinical assessment of patients with cancer (particularly due to its strict connection with cachexia and poor performance status), suggesting that inflammation is a further therapeutic target, potentially able to delay the onset of cachexia and/or death in cancer patients.
Other scores reflect cancer-associated immune changes focusing on specific mechanisms connected with hostdefense and tumour progression (NLR, thrombocytosis); regarding NLR, initial findings about a correlation with tumour aggressiveness were retrieved [52] , and a possible role not only of the preoperative value itself, but also of the whole NLR trend during patient history was observed [28, 39, 43, 46, 49] , suggesting a possible role as a follow-up marker (to be demonstrated in proper designed trials).
Different evidence is available for each of them as prognostic scores, but limits still exist.
Firstly, most of the studies are retrospective, and prospective evaluations are needed to confirm the literature data. Moreover, a better definition of cutoff values has to be pursued; actual values are very heterogeneous and sometimes differ in the same study between different centers [23] ; finally, it is still to be defined if different cancers are associated with different cutoffs or there is a common marker for prognosis to be used for all types of tumour. Investigators have just exceptionally compared effectiveness of different scores on predicting prognosis [6, 7] ; however, further and more homogeneous studies are warranted to understand which score is more efficient in predicting the level of systemic inflammation and prognosis in each specific type of cancer, also according to tumour stage.
However, despite limits, there is a rising evidence of the validity of prognostic inflammation-based scores and biomarkers. Their analysis allowed stratifying the subgroup of patients and to understand cancer-related physiological mechanisms [87] , configuring the first step towards a better multimodal therapy that, apart from cancer eradication, takes into account other targets to prolong patients' survival.
Inflammation is a promising target to improve perioperative outcome, and data show that anti-inflammatory techniques have a great potential in the perioperative period of cancer surgery [88] ; evidence exists for a higher cytokine activation in vitro in patients with higher BMI (proinflammatory condition) [89] . The ability to quantify inflammation could allow identifying patients more at risk of enhanced response and hypercytokinemia in the postoperative period; inflammation scores could be useful to stratify patients more at risk or with a potential better response to antiinflammatory strategies (and more worth to be treated with them), considering that the effect of NSAIDs and potentially all other anti-inflammatory techniques may depend on systemic inflammation level.
Regarding research, inflammatory scores could prevent failure of clinical trials testing drug candidate [90] and minimize unuseful exposure to ineffective therapies [90] . Inflammation scoring could clarify the real role of different drugs and techniques on outcome after cancer surgery, defining if different therapies are required for different patients. Forget et al. [23] showed that a single intraoperative administration of NSAIDs (ketorolac and diclofenac) could counteract effects of inflammation on cancer outcome and that this effect is twice greater in patients with NLR > 4 than in the whole series. Conversely, tumours with a slow growth, typically with 8 BioMed Research International a low level of inflammation and a small risk of early relapse, could have a smaller benefit of NSAIDs. This observation was done in a large retrospective series of 1,111 prostate cancer patients [91] and highlights the possible ability for NLR to guide drug choice on a specific target of patients. If data will be confirmed (NCT01806259) we could have indication to use NSAIDs on subtypes of patients in order to improve oncological outcome.
Moreover, discrepancies between studies focusing on the effects of regional analgesia or morphine in the perioperative period exist [92] ; this could be explained by their different efficacy in patients with different systemic inflammation. Inclusion of inflammation analysis in future clinical trials could clarify which patients are more indicated to be treated with regional techniques.
Finally, as opioids were advocated to have immunodeppressive action, able to facilitate tumour dissemination [92] , it would be useful to identify patients with enhanced inflammatory response, in order to understand if opioid therapy has beneficial effects on outcome in this specific subgroup of patients.
